New combo therapy aims to outsmart leukemia with less poison
NCT ID NCT07643103
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a new way to treat adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph-negative B-ALL). Instead of standard high-dose chemotherapy, patients receive a mix of low-dose chemo plus several targeted drugs (inotuzumab ozogamicin, venetoclax, blinatumomab) and possibly CAR-T cell therapy. The goal is to achieve a deep remission with fewer side effects. The study will enroll 32 participants and track how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Inotuzumab Ozogamicin, Venetoclax, Blinatumomab, and CD19 CAR-T cells
- What this could lead to
- If successful, this approach could offer a more effective and less toxic first-line treatment for Ph-negative B-ALL, potentially reducing the need for intensive chemotherapy.
- What could go wrong
- This is a small, early-phase (phase 2) trial with only 32 participants. The combination may cause unexpected side effects, and results may not apply to all patients. Long-term benefits are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PH- ACUTE LYMPHOBLASTIC LEUKEMIA (PH-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.